share_log

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

《每日生物技术脉搏》:罗氏的肺癌组合疗法未能通过后期研究,Adagio 在 COVID 抗体阳性数据上飙升,Amylyx 正在等待 Adcom 的判决
Benzinga Real-time News ·  2022/03/30 08:04
Here's a roundup of top developments in the biotech space over the last 24 hours.
以下是过去24小时生物技术领域的最新进展综述。
Stocks In Focus
关注的股票
J&J, ViiV Co-developed Long-Acting HIV Treatment Gets FDA Approval For Treating Adolescents
强生,欢跃联合开发的长效HIV疗法获得FDA批准用于治疗青少年
Johnson & Johnson's (NYSE:JNJ) Janssen unit said the U.S. Food and Drug Administration has approved Cabenuva (cabotegravir and rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents, who are 12 years of age or older, weigh at least 35 kg and are on a stable antiretroviral regimen, with no history of treatment failure, nor known or suspected resistance to either cabotegravir or rilpivirine.
强生(纽约证券交易所股票代码:JNJ)Janssen子公司表示,美国食品和药物管理局已经批准Cabenuva(卡波替格列韦和利培韦林)用于治疗病毒抑制青少年的HIV-1,这些青少年年龄在12岁或以上,体重至少35公斤,正在接受稳定的抗逆转录病毒治疗,没有治疗失败的历史,也没有已知或怀疑对卡波替格列韦或利培韦林产生耐药性。
Cabenuva...
C...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发